Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 100

Results For "report"

2004 News Found

AxoSim appoints Alif Saleh as CEO
People | June 14, 2024

AxoSim appoints Alif Saleh as CEO

Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer


Torrent Pharmaceuticals gets Form 483 with 5 observations for Indrad facility
Drug Approval | June 13, 2024

Torrent Pharmaceuticals gets Form 483 with 5 observations for Indrad facility

There was no observation related to data integrity reported


Honeywell introduces batch historian to digitalize manufacturing operations
Digitisation | June 11, 2024

Honeywell introduces batch historian to digitalize manufacturing operations

New software solution helps manufacturers digitalize and gain insights from data to increase efficiency


Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis
Clinical Trials | June 09, 2024

Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis

New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH


Sun Pharma to acquire stake in HaystackAnalytics
News | June 08, 2024

Sun Pharma to acquire stake in HaystackAnalytics

HaystackAnalytics is engaged in the business of developing genomic analysis software


Jemperli trial continues to show positive results for deficient (dMMR) rectal cancer
Clinical Trials | June 06, 2024

Jemperli trial continues to show positive results for deficient (dMMR) rectal cancer

Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response


Supriya Lifescience FY24 PAT up 32%
News | June 03, 2024

Supriya Lifescience FY24 PAT up 32%

The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23


Sun Pharma to present results of the Phase III PIVOTAL trial of Nidlegy in melanoma at ASCO 2024
Clinical Trials | June 01, 2024

Sun Pharma to present results of the Phase III PIVOTAL trial of Nidlegy in melanoma at ASCO 2024

PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy


Ascentage releases results from multiple clinical studies of its lead drug candidates
Clinical Trials | May 28, 2024

Ascentage releases results from multiple clinical studies of its lead drug candidates

These abstracts report on the company's three lead drug candidates, including olverembatinib


Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction
Clinical Trials | May 27, 2024

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction

Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression